



NEWS RELEASE

NeuroVive First Day of Trading on NASDAQ OMX Stockholm

Lund (Sweden) – April 10, 2013, NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, announces that its admission to NASDAQ OMX Stockholm will become effective and trading of the shares will start at 09.00 am (CET) today, 10th April 2013.

The stock will be listed as a Small Cap company within the Healthcare sector and traded under the ticker symbol, NVP. No new shares have been issued in conjunction with the listing on NASDAQ OMX Stockholm.

Mikael Bronnegard, CEO of NeuroVive Pharmaceutical (“NeuroVive”) said: *“The first day of trading on NASDAQ OMX Stockholm marks a new stage in our Company’s evolution and demonstrates the continuing growth and development of the business. Through this listing NeuroVive will gain international exposure within life science, and increase its access to a broader and deeper pool of investors. This will be crucial as we look to progress our product development programmes and build on our leading position in mitochondrial medicine to create further value for our shareholders.”*

About NeuroVive Pharmaceutical AB (publ)

NeuroVive Pharmaceutical AB (www.neurovive.com), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection.

NeuroVive’s products are based on development of cyclophilin inhibitors derived from different chemistry platforms. The drugs work by preventing the death of mitochondria in distressed cells and the subsequent cascade of intracellular biochemical events that lead to secondary tissue damage following an acute cardiac or traumatic brain injury.

NeuroVive’s lead product is CicloMulsion®, the first cyclophilin inhibitor for the treatment of reperfusion injuries following cardiac stenting. CicloMulsion® is currently in a 1000 patient Phase III clinical trial evaluating its ability to reduce reperfusion injuries in patients with myocardial infarction.

NeuroVive is also developing NeuroSTAT®, a cyclophilin inhibitor, which is entering a Phase IIa clinical trial in patients with severe traumatic brain injury. Both indications have huge medical need and for which there are currently no approved pharmaceutical treatment options. Both CicloMulsion® and NeuroSTAT® are special formulations of cyclosporine for use in acute cardiac and brain injury indications.

NeuroVive's pipeline includes novel cyclophilin inhibitors, and drug candidates that act on mitochondria to address energy regulation disorders.

Media and investor relations contacts

NeuroVive Pharmaceutical: Mikael Bronnegard

Email: info@neurovive.com

Phone No: +46 (0) 70 299 62 64

Citigate Dewe Rogerson: Nina Enegren / David Dible

Email: nina.enegren@citigatedr.co.uk

Phone No: +44 207 282 1050